Topics covered: Therapeutic antibodies segment, Restructuring of CDER and CBER divisions, Research into neurology and Alzheimers, Premium drug candidate opportunities, Positive clinical trials, Oncology drug trials, Molecule drugs and diagnostics, M&A Activity, International diversification, HCV drugs, Genetic engineering technologies, Financial market outlook, FDA Approval Process, Drug discovery, Big Pharma partnerships & joint ventures
